Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

Agios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221

October 15, 2014

 Once-Daily Oral Dose Selected From Ongoing Phase 1 Study of AG-221 in Hematologic Malignancies

Data From AG-120 to be Presented at EORTC-NCI-AACR 2014; AG-221 and AG-348 Data to be Presented at 2014 American Society of Hematology Annual Meeting

Company to Webcast R&D Day Today

Selecta Announces More than $20 Million in Equity Funding

Selecta Announces More than $20 Million in Equity Funding

October 15, 2014

WATERTOWN, Mass.–(BUSINESS WIRE)–Selecta Biosciences, Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced it has secured equity funding of more than $20 million from new and all of Selecta’s existing investors.

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

Selecta, JDRF and Sanofi Extend Collaboration to Develop a Synthetic Vaccine Particle Immunotherapy for Type 1 Diabetes

October 15, 2014

WATERTOWN, Mass.--(Business Wire)--Selecta Biosciences, Inc., and JDRF,

Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083

Acceleron Initiates Phase 1 Clinical Trial with Innovative Muscle Drug ACE-083

October 14, 2014

-- Locally administered investigational therapeutic designed to increase muscle mass in treated muscles --

-- Fourth internally discovered drug expands Acceleron’s clinical pipeline --

Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms

Syros Pharmaceuticals’ Scientific Founders Publish New Research on Gene Control Mechanisms

October 14, 2014

 Papers in Cell and Molecular Cell expand on importance of super-enhancers in regulating gene expression in normal and inflammatory states

WATERTOWN, MA, October 14, 2014 – Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today that recently published research from two of its scientific founders sheds new light on the crucial role of gene control mechanisms in cellular function.

Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity

Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity

October 13, 2014

   No sedation or ataxia observed and treatment was well tolerated

Company plans to initiate a Phase 2 trial this year

Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005

Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005

October 7, 2014

- Topically-administered protein therapeutic that blocks IL-1 receptor is in clinical development for dry eye disease and moderate to severe allergic conjunctivitis -

Oasys Water Named to the 2014 Global Cleantech 100

Oasys Water Named to the 2014 Global Cleantech 100

October 7, 2014

List Recognizes the Top Private Companies in Clean Technology

Boston, MA – October 7, 2014: Oasys Water, a world leader in innovative solutions for water treatment and desalination, today announced it was named in the prestigious 2014 Global Cleantech 100, produced by Cleantech Group, whose mission is to connect corporates to sustainable innovation through the i3 market intelligence platform, expert consulting services, and global events.

Seres Health Appoints Two New Board Members

Seres Health Appoints Two New Board Members

October 6, 2014

CAMBRIDGE, Mass., Oct. 6, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced the appointments of Richard N. Kender and Dr. Lorence H. Kim, to the company's board of directors. They each have extensive financial backgrounds which will be beneficial to the Seres team in achieving its business goals.

Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases

October 2, 2014

 – Co-led by New Investors, Merck Research Labs Venture Fund, Vertex Venture Holdings and Temasek –